Apr. 8, 2004  44  US 2004/0067216 Al  wherein:  R 2  and  R 3  are each independently hydrogen or methyl;  each L is independently hydrogen, chlorine, or fluorine;  each  Y  is independently hydrogen, chlorine, or fluorine;  and  each of the substituents on substituted heterocycle is  independently chlorine, fluorine, methoxy, ethoxy,  -OCF$_{3}$ ,  -OCHF$_{2}$ ,  methyl,  ethyl,  n-propyl,  -S-CH$_{3}$ ,  -N(CH$_{3}$ ) ,  and thiazolyl.  10. The composition according to claim 1, wherein the  complex comprises a compound selected from the group  consisting of:  ( aR,yS,2S)-N-( (3S,4S)-3,4-dihydro-3-hydroxy-2H-1- benzopyran-4-yl)-4-(1-furo[3,2-c ]pyridin-2-yl-1-meth› ylethyl)-y-hydroxy-a-(phenylmethyl)-2-[[(2,2,2-trif› luoroethyl)amino ]carbonyl]-1-piperazinepentanamide;  ( aR,yS  ,2S)-N-( (3S,4S)-3,4-dihydro-3-hydroxy-2H-1- benzopyran-4-y l)-y-hydroxy-4-[ ( 5-pheny 1-2-furanyl› )methy l ]-a-( 4-pyridinylmethyl)-2-[[(2,2,2-trifluoroet› hyl)amino ]-carbonyl]-1-piperazinepentanamide;  ( aR,yS,2S)-N-( (3S,4S)-3,4-dihydro-3-hydroxy-2H-1- benzopyran-4-yl)-y-hydroxy-4-[1-methyl-1-(1-phenyl› lH-pyrazol-3-y l)ethy 1 ]-a-( 3-pyridiny lmethy 1)-2-[[ (2,  2,2-trifluoroethyl)amino ]carbonyl ]-1- piperazinepentanamide;  ( aR,yS,2S)-N-( (3S,4S)-3,4-dihydro-3-hydroxy-2H-1- benzopyran-4-yl)-y-hydroxy-a-(phenylmethyl)-4-[[ 5- (2-pyridinyl)-2-furanyl ]me thy 1 ]-2-[[ (2,2,2-trifluoroet› hy l)-amino ]carbonyl]-1-piperazinepentanamide;  ( aR, yS,2S)-4-[[ 5-( 5-chloro-2-pyridiny 1)-2-furany 1 ]me› thyl]-N-( (3S,4S)-3,4-dihydro-3-hydroxy-2H-1-ben› zopyran-4-yl)-y-hydroxy-a-(phenylmethyl)-2-[[(2,2,2- trifluoroethyl)amino ]carbonyl ]-1- piperazinepentanamide;  ( aR,yS,2S)-N-(3S,4S)-3,4-dihydro-3-hydroxy-2H-1-ben› zopyran-4-yl]-y-hydroxy-4-[1-methyl-1-[ 5-(3-pyridi› ny 1)-2-oxazoly 1 ]ethyl ]-a-(pheny lmethy 1)-2-[[ (2,2,2- trifluoroethy l)amino ]carbonyl ]-1- piperazinepentanamide;  ( aR,yS,2S)-N-(3S,4S)-3,4-dihydro-3-hydroxy-2H-1-ben› zopyran-4-y 1 ]-y-hydroxy-4-[ 1-[ 5-( 5-methoxy-3-pyridi› ny 1)-2-oxazoly l ]-l-methylethyl]-a-(phenylmethyl)-2- [[ (2,2,2-trifluoroethyl)amino ]carbonyl]-1- piperazinepentanamide;  ( aR,yS,2S)-N-[ (3S,4S)-3,4-dihydro-3-hydroxy-2H-1- benzopyran-4-y 1 ]-y-hydroxy-4-[ 1-[ 5-( 5-fluoro-3-py› ridiny 1)-2-oxazoly l ]-l-methylethyl]-a-(phenylm› ethyl)-2-[[ (2,2,2-trifluoroethyl)amino ]carbonyl]-1- piperazinepentanamide;  ( aR,yS,2S)-N-[ (3S,4S)-3,4-dihydro-3-hydroxy-2H-1- benzopyran-4-yl]-y-hydroxy-4-[1-[1-( 5-fluoro-3-py› ridinyl)-lH-pyrazol-3-yl ]- l-methylethyl]-a-(phenylm› ethyl)-2-[[ (2,2,2-trifluoroethyl)amino ]carbonyl]-1- piperazinepentanamide;  ( aS,yS,2S)-4-[1-[ 5-( 4-chlorophenyl)-2-oxazolyl]-1-me› thylethyl ]-N-[ (3S,4S)-3,4-dihydro-3-hydroxy-2H-1- benzopyran-4-y 1 ]-a-( furo[2,3-c ]pyridin-2-y lmethy l)-y› hydroxy-2-[[ (2,2,2-trifluoroethy l)amino ]carbonyl ]-1- piperazinepentanamide;  9.  The composition according to claim 8, wherein the  complex comprises a compound of Formula (I) or a phar› maceutically acceptable salt thereof, wherein:  J  is  heterocycle, or substituted heterocycle;  heterocycle is  R 4  is  R $^{5 }$is  wherein:  each  Y  is independently hydrogen, halogen, C$_{1}$-C$_{6 }$ alkyl, fluorinated C$_{1 }$-C$_{6 }$ alkyl, or C$_{1 }$-C$_{4 }$ alkoxy; and  p is an integer from  O  to 2; and  substituted heterocycle is heterocycle as defined above  having one or more substituents independently  selected from halogen, C$_{1}$-C$_{4 }$ alkoxy, C$_{1}$-C$_{4 }$ alkyl,  fluorinated C$_{1}$-C$_{4 }$ alkoxy, fluorinated C$_{1 }$-C$_{4 }$ alkyl,  -S-CH$_{3}$ ,  -N(CH$_{3}$ ) ,  thiazolyl, and oxazolyl; and  Xis O or S; 